Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency.

What Was Tested

This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Who Took Part

The study group was 24 patients.

The age groups tagged for this paper are adults, both men and women.

The effects of 6 months' treatment with recombinant human growth hormone (rhGH) on serum lipids and lipoproteins were assessed in 24 adult patients with GH deficiency in a double-blind, placebo-controlled trial.

How the Study Was Run

The researchers set it up as a double-blind and placebo-controlled study.

Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

What Was Measured

The subject headings attached to it are Apolipoprotein A-I, Apolipoproteins B, Cholesterol, Cholesterol, HDL, Cholesterol, LDL, Growth Hormone and Lipids.

What This Means in Plain Language

The paper is a double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 24 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1993 (Metabolism: clinical and experimental), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.